Take a trial of UK to unlock this pageFind out more
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 23rd Oct, paid: 11th Nov more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +18.7%

FINANCIAL BRIEF: For the six months ended 28 June 2014, Smith & Nephew plc revenues increased 3% to $2.22B. Net income decreased 12% to $239M. Revenues reflect Advance Surgical Devices segment increase of 4% to $1.57B, Advanced Wound Management segment increase of 1% to $652M, Emerging and International Markets segment increase of 16% to $317M, United States segment increase of 3% to $944M, Established Markets segment increase of 1% to $826M. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
B-
B-

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 28th Jun '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: $17.7 (+12.51% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +11.7% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
19 brokers Broker Consensus Trend
Broker Recommendations for Smith & Nephew
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 11 2 6

Named Brokers and Analysts
Jefferies & Company, Inc. Martin Brunninger , Credit Suisse Christoph Gretler , Sanford Bernstein Lisa Bedell Clive , Investec Bank (UK) Plc Nicholas Keher , Canaccord Genuity William Plovanic , Nomura Securities , Jefferies International Ltd , Panmure Gordon Savvas Neophytou , Numis Securities Sally Taylor , Edison Investment Research , Societe Generale Justin Smith , Berenberg Tom Jones , Equita SIM, European Equity Research Fabio Fazzari , Charles Stanley Rae Ellingham , Shore Capital Stockbrokers Brian White , Morningstar, Inc. Debbie Wang , Day by Day Valérie GASTALDY , Matrix Corporate Capital LLP , and 1 unnamed other

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management. It operates on a worldwide basis and has distribution channels in over 90 countries. Orthopaedic reconstruction implants include hip, knee and shoulder joints, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. Endoscopy business develops and commercialises endoscopic (minimally invasive surgery) techniques, educational programmes and services. Advanced Wound Management business offers a range of products from initial wound bed preparation through to full wound closure. In May 2012, it acquired Kalypto Medical, Inc. In May 2014, the Company acquired ArthroCare Corporation.

Directors: Olivier Bohuon (CEO) 55, Julie Brown (CFO) 51, Rodrigo Bianchi (CEX) 54, Michael Frazzette (CEX) 52, R. Gordon Howe (CEX) 51, Roger Teasdale (CEX) 46, Francisco Vega (CEX) 52, John Campo (OTH) 59, Helen Maye (OTH) 54, Cyrille Petit (OTH) 43, Roberto Quarta (NEC) 64, Ian Barlow (NID) 62, Virginia Bottomley (NID) 66, Michael Friedman (NID) 70, Brian Larcombe (NID) 60,

No. of Employees: 14,000 No. of Shareholders: 18,188


Last Annual December 31st, 2013
Last Interim June 28th, 2014
Shares in Issue 893,538,804
Free Float 891.1m (99.7%)
ISIN GB0009223206

SN. Share Price Performance SN. Quote
981.5p
-9.0  -0.9%
Traded 5:02pm · Minimum 15 min delayed · NMS: 2.00k

Latest SN. News Announcements (delayed)

Upcoming SN. Events
Thursday 30th October, 2014
Q3 2014 Smith & Nephew Earnings Release
Thursday 30th October, 2014
Q3 2014 Smith & Nephew PLC Earnings Call
Tuesday 11th November, 2014
Smith & Nephew PLC Capital Markets Event
Monday 2nd February, 2015 (estimate)
Q4 2014 Smith & Nephew Earnings Release

Recent ↓
Wednesday 22nd October, 2014
Dividend For SNN
Tuesday 14th October, 2014
Smith & Nephew PLC Split For SNN
Thursday 18th September, 2014
Smith & Nephew PLC at Bernstein Strategic Decisions Conference
Friday 1st August, 2014
Q2 2014 Smith & Nephew PLC Earnings Call
Friday 1st August, 2014
Q2 2014 Smith & Nephew Earnings Release
Friday 20th June, 2014
Smith & Nephew PLC at Citi European Healthcare Conference
Wednesday 7th May, 2014
Smith & Nephew at Deutsche Bank Healthcare Conference
Thursday 1st May, 2014
Q1 2014 Smith & Nephew Earnings Conference Call
Thursday 1st May, 2014
Q1 2014 Smith & Nephew Earnings Release
Thursday 17th April, 2014
Dividend For SNN


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy SN.

Access SN. Analytics Now!

FREE TRIAL or TAKE THE TOUR